Hemostatic factors and cardiovascular disease in active rheumatoid arthritis: An 8 year followup study

Journal of Rheumatology

Volumn 27, Issue 1, 2000, Pages 71-75

  Wållberg Jonsson, Solveig ^a   Cederfelt, Maria ^a   Rantapää Dahlqvist, Solbritt ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cardiovascular disease; Fibrinolysis; Hemostase factors; Inflammation; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RESPONSE; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FIBRINOLYSIS; FOLLOW UP; HEMOSTASIS; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; THROMBOCYTE ACTIVATION; VASCULITIS;

ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEMOSTASIS; HUMANS; LIPIDS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 0342470541     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Myllykangas-Luosujärvi RA, Aho K, Isomäki HA. Mortality in rheumatoid arthritis. Semin Arthritis Rheum 1995;25:193-202.
2. Wållberg-Jonsson S, Öhman M-L, Rantapää-Dahlqvist S. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 1997;24:445-51.
3. Turner LW, Lansbury J. Low diastolic pressure as a clinical feature of rheumatoid arthritis and its possible etiologic significance. Am J Med Sci 1954;227:503-8.
4. Cathcart ES, Spodick DH. Rheumatoid heart disease. A study of the incidence and nature of cardiac lesions in rheumatoid arthritis. J Med 1962;266:959-64.
5. Hakala M, Ilonen J, Reijonen H, Knip M. Koivisto O, Isomäki H. No association between rheumatoid arthritis and insulin dependent diabetes mellitus: An epidemiologic and immunologic study. J Rheumatol 1992;19:856-8.
6. Hazes JMW, Dijkmans BAC, Vandenbroucke JP, de Vries RRP, Cats A. Lifestyle and the risk of rheumatoid arthritis: cigarette smoking and alcohol consumption. Ann Rheum Dis 1990;49:980-2.
7. Voigt LF, Koepsell TD, Nelson JL, Dugowson CE, Daling JR. Smoking, obesity, alcohol consumption and the risk of rheumatoid arthritis. Epidemiology 1994;5:525-32.
8. Svenson KLG. Lithell H, Hällgren R, Selinus I, Vessby B. Altered serum lipoproteins and enhanced lipoprotein elimination in patients with rheumatoid arthritis and other chronic inflammatory arthritides. Arch Intern Med 1987;147:1912-6.
9. Rantapää-Dahlqvist S, Wållberg-Jonsson S, Dahlén G. Lipoprotein(a), lipids, and lipoproteins in patients with rheumatoid arthritis. Ann Rheum Dis 1991:50:366-8.
10. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
11. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994;331:417-24.
12. Wållberg-Jonsson S. On inflammation and cardiovascular disease in patients with rheumatoid arthritis [dissertation]. Umeå. Sweden: University of Umeå. 1996, 133 p.
13. Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991;66:351-5.
14. Hamsten A, Walldius G, Szamosi A, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987;2:3-8.
15. Heart DA, Fritzler MJ. Regulation of plasminogen activators and their inhibitors in rheumatic disease: New understanding and the potential for new directions. J Rheumatol 1989;16:1184-91.
16. Wållberg Jonsson S, Dahlén G, Nilsson TK, Rånby M, Rantapää Dahlqvist S. Tissue plasminogen activator, plasminogen activator inhibitor-1 and von Willebrand factor in rheumatoid arthritis. Clin Rheumatol 1993;12:318-24.
17. Pottinger BE, Read RC, Paleolog EM, Higgings PG, Pearson JD. von Willebrand factor is an acute phase reactant in man. Thromb Res 1989;53:387-94.
18. Bachmann F. Fibrinolysis. In: Verstraete M, Vermylen J, Lijnen R, Arnout J, editors. Thrombosis and haemostasis 1987. Leuven: Leuven University Press; 1987:227-65.
19. de Bono D. Significance of raised plasma concentrations of tissue-type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischemic heart disease. Br Heart J 1994;71:504-7.
20. Meyer D, Girma J-P. von Willebrand factor: structure and function. Thromb Haemost 1993;70:99-104.
21. Wang DL, Pan YT, Wang JJ, Cheng CH. Liu CY. Demonstration of a functionally active tPA-like plasminogen activator in human platelets. Thromb Haemost 1994;71:493-8.
22. Seriolo B, Accordo S, Fasciolo D, Sulli A, Bertolini S. Cutolo M. Lipoprotein(a) and anticardiolipin antibodies as risk factors for vascular disease in rheumatoid arthritis. Thromb Haemost 1995;74:793-810.
23. Lascalzo J, Weinfield M. Fless GM. Scanu AM. Lipoprotein(a) fibrinn binding, and plasminogen activation. Arteriosclerosis 1990;10:240-5.
24. Ropes MW, Bennet GA, Cobb S. Diagnostic criteria for rheumatoid arthritis. Ann Rheum Dis 1959;18:49-53.
25. Jansson J-H, Norberg B, Nilsson TK. Impact of acute phase on concentrations of tissue plasminogen activator and plasminogen activator inhibitor in plasma after deep vein thrombosis or open heart surgery. Clin Chem 1989;35:1544-5.
26. Nomenclature and criteria for diagnosis of ischemic heart disease: report of the Joint International Society and Federation of Cardiology/World Health Organisation Task Force on Standardization of Clinical Nomenclature. Circulation 1979; 59:607-9.
27. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987;69:1691-5.
28. Wållberg Jonsson S, Rantapää Dahlqvist S, Nordmark L, Rånby M. Mobilization of fibrinolytic enzymes in synovial fluid and plasma of rheumatoid arthritis and spondylarthropathy. Relation to radiologie destruction. J Rheumatol 1996;23:1704-9.
29. Kopeikina LT, Kamper EF, Koutsokos V, Bassiakos Y, Stavridis I. Imbalance of tissue-type plasminogen activator and its specific inhibitor in patients with rheumatoid arthritis associated with disease activity. Clin Rheumatol 1997;16:254-60.
30. Angles-Cano E, Sultan Y, Cluvel JP. Predisposing factors to thrombosis in systemic lupus erythematosus. J Lab Clin Med 1979;94:313-23.
31. Nusinow SR, Federici AB, Zimmerman TS, Curd JG. Increased von Willebrand factor antigen in the plasma of patients with vasculitis. Arthritis Rheum 1984;27:1405-10.
32. Belch JJF, Zoma AA, McLaughlin K. Forbes CD, Sturrock RD. Vascular damage and factor-VIII-related antigen in the rheumatic diseases. Rheumatol lnt 1987;7:107-11.
33. Blann AD, Hopkins J, Winkles J, Wainwright AC. Plasma and serum von Willebrand factor antigen concentrations in connective tissue disorders. Ann Clin Biochem 1992;29:67-71.
34. Lau CS, McLaren M, Hanslip J, Kerr MJ, Belch JJF. Abnormal plasma fibrinolysis in patients with rheumatoid arthritis and impaired endothelial fibrinolytic response in those complicated by vasculitis. Ann Rheum Dis 1993,52:643-9.
35. Mussoni L, Pintucci G, Romano G, De Benedetti F, Massa M, Martini A. Decreased fibrinolytic activity in juvenile chronic arthritis. Ann Rheum Dis 1990;49:973-5.
36. Jordan JM, Bates Allen N, Pizzo SV. Defective release of tissue plasminogen activator in systemic and cutaneous vasculitis. Am J Med 1987;82:397-400.
37. Flipo R-M. Janin A, Hachulla E, et al. Labial salivary gland biopsy assessment in rheumatoid vasculitis. Ann Rheum Dis 1994; 53:648-52.
38. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993;118:956-63.
39. Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn PF. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 1991;84:613-7.
40. Myllykangas-Luosujärvi R, Aho K, Isomäki H. Death attributed to antirheumatic medication in a nationwide series of 1666 patients with rheumatoid arthritis who have died. J Rheumatol 1995;22:2214-7.
41. Raynauld J-P, Wolfe F, Sibley JT, Fries JF. Mortality by cardiovascular disease and use of corticosteroids in rheumatoid arthritis [abstract]. Arthritis Rheum 1993; Suppl 36:193.
42. Raynauld J-P. Cardiovascular mortality in rheumatoid arthritis: How harmful are corticosteroids? [editorial]. J Rheumatol 1997;24:415-6.
43. Conlan MG, Folsom AR, Finch A. et al. Associations of Factor VIII and von Wiliebrand Factor with age, race, sex, and risk factors for atherosclerosis. Thromb Haemost 1993;70:380-5.